Strontium ranelate related Stevens-Johnson syndrome: a case report.

Abstract

Strontium ranelate is a relatively new medication with good safety profile for the treatment of postmenopausal osteoporosis. However, severe cutaneous adverse drug reactions have been reported, such as drug rash with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). We report the case of a 70-year-old woman who developed multiple itching erythematous macules and plaques about 1 month after beginning strontium ranelate medication. The cutaneous lesions progressed over the entire body with severe oral and ocular mucosa involvement. Probable mild SJS was diagnosed, compatible with the pathology findings, and strontium ranelate was discontinued immediately. Systemic methylprednisolone was administered to suppress the overactive immune system and ameliorate cutaneous symptoms. With early recognition and prompt treatment, the patient's prognosis was good.

• Authors: C-Y Yang, C-H Chen, H-Y Wang, H-L Hsiao, Y-H Hsiao, W-H Chung
• Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (Osteoporos Int) Vol. 25 Issue 6 Pg. 1813-6 (Jun 2014) ISSN: 1433-2965 [Electronic] England
• PMID: 24687387 (Publication Type: Case Reports, Journal Article)

Chemical References

• Bone Density Conservation Agents
• Thiophenes
• strontium ranelate

Topics

• Aged
• Bone Density Conservation Agents (adverse effects, therapeutic use)
• Drug Eruptions (etiology)
• Female
• Humans
• Osteoporosis, Postmenopausal (drug therapy)
• Stevens-Johnson Syndrome (etiology)
• Thiophenes (adverse effects, therapeutic use)